An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in...

Keywords

MedicineIrinotecanOxaliplatinFolinic acidRegimenBolus (digestion)FluorouracilNeutropeniaGastroenterologyMucositisInternal medicineChemotherapySurgeryCancerColorectal cancer

Affiliated Institutions

Related Publications

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Salah‐Eddin Al‐Batran , J. T. Hartmann , Stephan Probst +17 more

Purpose This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer. Patie...

2008 Journal of Clinical Oncology 775 citations

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Sergei Tjulandin , Alejandro Majlis , Manuel Constenla +9 more

Purpose In the randomized, multinational phase II/III trial (V325) of untreated advanced gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorourac...

2006 Journal of Clinical Oncology 1912 citations

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

Kate Sumpter , Catherine Harper‐Wynne , David Cunningham +9 more

2005 British Journal of Cancer 143 citations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-ba...

2019 The Lancet 2355 citations

Publication Info

Year: 2003
Type: article
Volume: 14
Issue: 3
Pages: 481-489
Citations: 112
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

112

OpenAlex

Cite This

APA Style

                            
                                
                                    Marc Ychou, 
                                
                                    Thierry Conroy, 
                                
                                    Jean‐François Seitz
                                
                                et al.
                            
                            (2003). 
                            An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. 
                            Annals of Oncology
                            , 14
                            (3)
                            , 481-489.
                            https://doi.org/10.1093/annonc/mdg119
                        

Identifiers

DOI: 10.1093/annonc/mdg119